Dashboard
Manage Tickers

SUPNSUPERNUS PHARMACEUTICALS, INC.

Nasdaq supernus.com


$ 31.48 $ -0.44 (-1.38 %)    

Thursday, 08-Aug-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 449.23 $ 13.30 (3.06 %)
DIA $ 395.05 $ 6.75 (1.74 %)
SPY $ 531.28 $ 11.99 (2.31 %)
TLT $ 95.30 $ -0.59 (-0.62 %)
GLD $ 224.00 $ 3.46 (1.57 %)
$ 31.48
$ 31.43 x 200
-- x --
-- - --
$ 21.99 - $ 35.44
662,765
na
1.75B
$ 0.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 04-13-2022 12-31-2021 10-K
12 11-05-2021 09-30-2021 10-Q
13 08-06-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 03-08-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 08-17-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 02-28-2020 12-31-2019 10-K
20 11-08-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 03-01-2019 12-31-2018 10-K
24 11-09-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-01-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-03-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 01-20-2017 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-09-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-06-2015 03-31-2015 10-Q
39 03-12-2015 12-31-2014 10-K
40 11-12-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

supernus-pharmaceuticals-shares-are-trading-higher-after-the-company-reported-better-than-expected-q2-financial-results-and-raised-its-fy24-revenue-guidance
Supernus Pharmaceuticals shares are tradin...
08/07/2024 14:44:22

supernus-raises-2024-total-revenue-guidance-from-580m-620m-to-600m-625m-vs-60012m-est
Supernus Raises 2024 Total Revenue Guidanc...
08/06/2024 20:21:31

supernus-pharmaceuticals-q2-2024-gaap-eps-036-beats-005-estimate-sales-168300m-beat-148851m-estimate
Supernus Pharmaceuticals Q2 2024 GAAP EPS ...
08/06/2024 20:14:29

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate...

supernus-resubmits-nda-to-fda-for-spn-830-apomorphine-infusion-device
Supernus Resubmits NDA To FDA For SPN-830 ...
08/01/2024 21:30:30

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products fo...

supernus-pharmaceuticals-announces-interim-analysis-data-from-phase-2a-clinical-study-of-spn-817-for-treatment-resistant-seizures
Supernus Pharmaceuticals Announces Interim...
05/23/2024 20:09:21

supernus-pharmaceuticals-reiterates-fy24-revenue-580m-620m-vs-601461m-est
Supernus Pharmaceuticals Reiterates FY24 R...
05/08/2024 21:25:29

supernus-pharmaceuticals-q1-sales-143600m-miss-145832m-estimate
Supernus Pharmaceuticals Q1 Sales $143.600...
05/08/2024 21:21:47

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly sales of $143.600 million which missed the analyst consensus estimate...

m8-pharmaceuticals-signs-an-exclusive-licensing-agreement-with-supernus-pharmaceuticals-to-seek-regulatory-approval-and-commercialize-qelbree-under-m8s-trademark-in-latin-america
M8 Pharmaceuticals Signs An Exclusive Lice...
05/07/2024 14:03:00

M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with...

supernus-pharmaceuticals-faces-second-fda-rejection-for-investigational-device-for-parkinsons-disease
Supernus Pharmaceuticals Faces Second FDA ...
04/08/2024 14:11:37

Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for ...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
04/08/2024 12:09:45

supernus-provides-regulatory-update-for-spn-830-fda-has-issued-a-crl-in-response-to-the-cos-nda-for-spn-830-indicating-that-the-review-cycle-for-the-application-is-complete-but-that-the-application-is-not-ready-for-approval-in-its-present-form
Supernus Provides Regulatory Update For SP...
04/08/2024 12:06:03

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products fo...

piper-sandler-maintains-overweight-on-supernus-pharmaceuticals-lowers-price-target-to-41
Piper Sandler Maintains Overweight on Supe...
02/28/2024 15:40:29

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and lowers the price...

supernus-sees-fy24-total-revenue-580m-620m-vs-62252m-est
Supernus Sees FY24 Total Revenue $580M-$62...
02/27/2024 22:15:26

recap-supernus-pharmaceuticals-q4-earnings
Recap: Supernus Pharmaceuticals Q4 Earnings
02/27/2024 21:30:12

supernus-pharmaceuticals-q4-2023-adj-eps-039-misses-055-estimate-sales-16431m-beat-15503m-estimate
Supernus Pharmaceuticals Q4 2023 Adj EPS $...
02/27/2024 21:30:06

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.39 per share which missed the analyst consensus estima...

earnings-scheduled-for-february-27-2024
Earnings Scheduled For February 27, 2024
02/27/2024 10:01:31

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

supernus-pharmaceuticals-wins-infringement-and-validity-case-on-trokendi-xr
Supernus Pharmaceuticals Wins Infringement...
02/05/2024 13:36:59

United States District Court for the District of New Jersey ruled that Torrent Pharmaceuticals Ltd. and its subsidiary, Torrent...

supernus-pharmaceuticals-has-granted-rights-to-knight-therapeutic-to-seek-regulatory-approval-and-commercialize-qelbree-in-canada-for-attention-deficit-hyperactivity-disorder-financial-terms-of-the-agreement-were-not-disclosed
Supernus Pharmaceuticals Has Granted Right...
12/19/2023 12:40:43

botox-and-similar-injections-have-associated-risks-consumer-group-pushes-for-stronger-warnings
Botox And Similar Injections Have Associat...
12/12/2023 19:04:27

Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regardi...

piper-sandler-maintains-overweight-on-supernus-pharmaceuticals-raises-price-target-to-43
Piper Sandler Maintains Overweight on Supe...
11/09/2023 19:56:59

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION